A Thermostable mRNA Vaccine against COVID-19

By Na-Na Zhang, Xiao-Feng Li, Yongqiang Deng, Hui Zhao, Yi-Jiao Huang, Guan Yang, Weijing Huang, Peng Gao, Chao Zhou, Rong-Rong Zhang and 21 more. Cell, 2020

598 citations recorded by the source corpus.

There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (called ARCoV). Intramuscular immunization of ARCoV mRNA-LNP elicited robust neutralizing antibodies against SARS-CoV-2 as well as a Th1-biased cellular response in mice and non-human primates. Two doses of ARCoV immunization in mice conferred complete protection against the challenge of a SARS-CoV-2 mouse-adapted strain. Additionally, ARCoV is manufactured as a liquid formulation and can be stored at room temperature for at least 1 week. ARCoV is currently being evaluated in phase 1 clinical trials.

Subfields: Infectious Diseases, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/89744e35b95d0e269d46e1bf2f3d7c3b72d73e37

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability (2021, unknown): “Alternatively, the translation efficacy of mRNA encoding non-fluorescent antigens can be determined using an enzyme-linked immunosorbent assay (ELISA), or western blotting techniques as has been used previously to analyze the stability of mRNA encoding the receptor-binding domain (RBD) of SARS-CoV-2”
mRNA Vaccines in the COVID-19 Pandemic and Beyond. (2021, methodology): “This vaccine induced potent neutralizing antibody responses, CD4+ and CD8+ T cell responses, and protection from SARS-CoV-2 infection in mice after prime-boost immunizations with 2 and 10μg doses (40).”